Fig. 3: SP1 upregulation facilitated the increase in BRPF1 expression.
From: Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer
a The BRPF1 promoter contains two SP1 putative binding sites. b The expression of SP1 was positively correlated with the expression of BRPF1 in TCGA HCC cohort (R2 = 0.3238, P < 0.0001, linear regression, n = 50). c Inactivation of SP1 by siSP1 reduced the mRNA expression of BRPF1 and SP1 in HEK293T cells, while the expression of CASC1, a non-SP1 target, remained unchanged. d Treatment with siSP1 decreased BRPF1 promoter activity, but not the activity of SP1 binding site mutated BRPF1 promoter in HEK293T cells. e 20 nM mithramycin A, a SP1 inhibitor, reduced BRPF1 promoter activity in HEK293T cells after 48-h treatment. f 20 nM mithramycin A reduced the mRNA expression of BRPF1 in MHCC97L after 48-h treatment. Error bars indicate mean ± SD. Data were compared by independent t-test unless indicated otherwise. Results were repeated at least three times. **P < 0.01, ***P < 0.001, ****P < 0.0001, ns not significant vs. mock or siNTC as indicated.
